Tekla Capital Management LLC Lowered Gilead Sciences INC (GILD) Holding by $9.13 Million

Gilead Sciences, Inc. (NASDAQ:GILD) LogoInvestors sentiment increased to 1.02 in Q1 2019. Its up 0.42, from 0.6 in 2018Q4. It improved, as 64 investors sold GILD shares while 421 reduced holdings. 115 funds opened positions while 381 raised stakes. 961.76 million shares or 3.38% less from 995.36 million shares in 2018Q4 were reported. The Maryland-based Fort LP has invested 0.63% in Gilead Sciences, Inc. (NASDAQ:GILD). Old Republic Corp reported 220,500 shares stake. Morgan Dempsey Management has invested 1.05% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Brown Advisory Ltd Liability Company holds 0.35% or 22,586 shares. Moreover, Nelson Roberts Advsr Lc has 1.13% invested in Gilead Sciences, Inc. (NASDAQ:GILD). 17,181 were accumulated by Plancorp Lc. 1.72 million were accumulated by State Board Of Administration Of Florida Retirement Sys. Arga Inv Mgmt Limited Partnership has 0.41% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 42,104 shares. 300,000 were accumulated by Masters Ltd Liability Com. Price T Rowe Md reported 12.02M shares. Blb&B Lc, a Pennsylvania-based fund reported 3,660 shares. Pub Sector Pension Inv Board accumulated 235,755 shares. Carnegie Capital Asset Mgmt Ltd Company stated it has 13,286 shares or 0.06% of all its holdings. Great West Life Assurance Communications Can has invested 0.31% in Gilead Sciences, Inc. (NASDAQ:GILD). Advisory Alpha Ltd Llc stated it has 0% in Gilead Sciences, Inc. (NASDAQ:GILD).

Tekla Capital Management Llc decreased its stake in Gilead Sciences Inc. (GILD) by 7.43% based on its latest 2019Q1 regulatory filing with the SEC. Tekla Capital Management Llc sold 140,458 shares as the company’s stock declined 0.97% while stock markets rallied. The institutional investor held 1.75M shares of the health care company at the end of 2019Q1, valued at $113.73M, down from 1.89M at the end of the previous reported quarter. Tekla Capital Management Llc who had been investing in Gilead Sciences Inc. for a number of months, seems to be less bullish one the $84.25 billion market cap company. The stock increased 0.11% or $0.07 during the last trading session, reaching $66.26. About 4.03M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 2.61% since July 14, 2018 and is downtrending. It has underperformed by 7.04% the S&P500.

Tekla Capital Management Llc, which manages about $1.06 billion and $2.46 billion US Long portfolio, upped its stake in Pra Health Sciences Inc. by 73,077 shares to 143,537 shares, valued at $15.83M in 2019Q1, according to the filing. It also increased its holding in Pfizer Inc. (NYSE:PFE) by 553,972 shares in the quarter, for a total of 2.07 million shares, and has risen its stake in Amgen Inc. (NASDAQ:AMGN).

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 24. They expect $1.67 EPS, down 4.57 % or $0.08 from last year’s $1.75 per share. GILD’s profit will be $2.12 billion for 9.92 P/E if the $1.67 EPS becomes a reality. After $1.67 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Bizjournals.com which released: “Why Gilead could pay more than $2 billion in deal with this small S.F. biotech – San Francisco Business Times” on June 19, 2019, also Finance.Yahoo.com with their article: “Gilead Sciences (GILD) Gains But Lags Market: What You Should Know – Yahoo Finance” published on July 03, 2019, Nasdaq.com published: “Should Value Investors Consider Gilead (GILD) Stock Now? – Nasdaq” on November 21, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Nasdaq.com and their article: “Noteworthy Tuesday Option Activity: UAL, GILD, HP – Nasdaq” published on May 28, 2019 as well as Nasdaq.com‘s news article titled: “Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs – Nasdaq” with publication date: June 20, 2019.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 10 analysts covering Gilead Sciences (NASDAQ:GILD), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Gilead Sciences has $95 highest and $68 lowest target. $80.27’s average target is 21.14% above currents $66.26 stock price. Gilead Sciences had 22 analyst reports since February 12, 2019 according to SRatingsIntel. As per Tuesday, March 5, the company rating was maintained by Cantor Fitzgerald. The rating was downgraded by Citigroup on Tuesday, February 12 to “Neutral”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Sunday, March 17 by Piper Jaffray. Mizuho maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Tuesday, February 26. Mizuho has “Buy” rating and $88 target. The firm has “Buy” rating given on Friday, June 21 by Mizuho. The rating was maintained by Oppenheimer on Tuesday, March 19 with “Buy”. As per Wednesday, April 10, the company rating was upgraded by UBS. The rating was maintained by Mizuho on Friday, March 15 with “Buy”. The stock has “Strong Buy” rating by Raymond James on Tuesday, February 12. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Market Perform” rating given on Tuesday, February 12 by Wells Fargo.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.